From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Learn how one pharmaceutical manufacturer leveraged IntegriChain’s technology to identify and close gaps in their 867 data reporting. This large pharmaceutical manufacturer developed a blockbuster drug indicated for many types of cancers. They generated more than $7 billion dollars in revenue and recognized the growing strategic business value of timely and accurate data. After heavily investing in Master Data and System Integration (MDSI) technology, data sources and personnel, they identified gaps in syndicated DDD data and 867 data.
Missing 867 data elements impacted sales operations, while missing doctor and geolocation data caused downstream problems for sales territory assignment and account planning. These data issues were compounded by the time lag of about 45 days post sale. MDSI leadership knew they had to close the gaps in 867 data and they found a solution with IntegriChain’s patient matching, national and subnational data sets and data extracts.
Download the case study below to learn how this manufacturer was able to solve their 867 data gaps and streamline their sales pipeline.
